InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,460.48
(
-0.41%
)
US TECH 100
19,181.60
(
-0.43%
)
Dow Jones
39,118.86
(
-0.12%
)
Brent Oil
84.85
(
0.00%
)
Bitcoin
61,543.74
(
1.07%
)
Post# of 252431
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 832
Posts 119956
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: None

Tuesday, 01/30/2007 7:06:26 AM

Tuesday, January 30, 2007 7:06:26 AM

Post# of 252431
ZGEN Enters Phase-1 with Peg-Interferon Lambda for HCV

http://biz.yahoo.com/prnews/070130/sftu019.html?.v=92

>>
Tuesday January 30, 6:00 am ET

New Treatments Needed for Patients With Hepatitis C

SEATTLE, Jan. 30 /PRNewswire-FirstCall/ -- ZymoGenetics, Inc. (Nasdaq: ZGEN ) today announced that the company has initiated a Phase 1 safety and pharmacokinetic study of PEG-Interferon lambda (IL-29) in healthy volunteers. The Phase 1 study is part of a clinical development program designed to evaluate PEG-Interferon lambda as a potential treatment for patients with hepatitis C and other viral diseases.

"This clinical trial highlights the breadth of our pipeline and reflects our intense commitment to finding new treatments for patients. ZymoGenetics' development programs now encompass hemostasis, cancer, autoimmune and viral diseases," said Bruce L.A. Carter, Ph.D., President and CEO of ZymoGenetics. "We believe PEG-Interferon lambda could serve as an effective alternative in providing therapy for viral infections such as hepatitis C, with the potential for fewer side effects than the current standard of care."

The native human protein Interferon lambda is generated by the immune system in response to viral infection. It mediates anti-viral activity through a receptor that is distinct from that used by Interferon alpha and is generally present on fewer cell types within the tissues of the body. Receptors for Interferon lambda are present on several important sites of viral infection, most notably cells of the lung and liver. ZymoGenetics' product candidate, recombinant PEG-Interferon lambda, has shown in vitro anti-viral activity against several viruses, including hepatitis C.

About Hepatitis C

Chronic infection with hepatitis C virus (HCV) is a leading cause of cirrhosis, liver failure, and hepatocellular carcinoma worldwide. In the United States, it is estimated that HCV is associated with up to 20,000 deaths per year, and is the main indication for liver transplantation. An estimated 4.1 million people in the United States have been exposed to HCV, and approximately 3.2 million have chronic HCV infection. Without effective intervention, the National Institutes of Health project that the number of deaths from chronic HCV infection may triple in the next 10-20 years.

Current Standard of Care for Hepatitis C

The current standard of care for chronic HCV infection involves treatment with Interferon alpha and ribavirin. This form of HCV therapy has been associated with a number of significant side effects including flu-like symptoms, anorexia, depression, hemolytic anemia and myelosuppression. This side-effect profile often necessitates additional medications to manage the side effects, and can lead to early discontinuation of treatment and poor adherence to prescribed therapy, leading to worsened treatment outcomes. Currently, the response rates for the most common form of HCV in the United States to standard treatment are only 50%. Therefore, there remains a need for better tolerated and more effective therapy for HCV infection. The development of PEG-Interferon lambda is intended to provide such an alternative to PEG-Interferon alpha.

About ZymoGenetics

ZymoGenetics creates novel protein drugs with the potential to significantly help patients fight their diseases. The Company is developing a diverse pipeline of potential proprietary product candidates that are moving into and through clinical development. These candidates span a wide array of clinical opportunities that include bleeding, autoimmune and viral diseases and cancer. ZymoGenetics intends to commercialize these product candidates through internal development, collaborations with partners, and out-licensing of patents from its extensive patent portfolio. For further information, visit http://www.zymogenetics.com .
<<

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up